SAB Biotherapeutics Inc (SABS) — Defensive Interval Ratio
SAB Biotherapeutics Inc (SABS) has a Defensive Interval Ratio of 2974 days as of December 2025. Defensive assets of $87.04 Million (cash $-, short-term investments $86.09 Million, receivables $946.78K) cover 2974 days of daily cash needs of $29.26K/day. Check SABS tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
SAB Biotherapeutics Inc Defensive Interval Ratio (2019–2025)
This chart shows how SAB Biotherapeutics Inc's Defensive Interval Ratio has evolved across 7 annual periods from 2019 to 2025. As of December 2025, the ratio stands at 2974 days, meaning defensive assets of $87.04 Million can fund 2974 days of operations without new revenue. Also explore how fast is SAB Biotherapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Defensive Interval Ratio for SAB Biotherapeutics Inc (2019–2025)
The table below presents the year-by-year Defensive Interval Ratio for SAB Biotherapeutics Inc from 2019 to 2025, covering 7 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see market cap of SAB Biotherapeutics Inc.
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 2974 days | $87.04 Million | $29.26K/day | $- | $86.09 Million | ▲ +2429 days |
| 2024 | 545 days | $11.92 Million | $21.86K/day | $- | $11.86 Million | ▲ +545 days |
| 2023 | 0 days | $0.00 | $29.63K/day | $- | $0.00 | ▼ -135 days |
| 2022 | 135 days | $5.56 Million | $41.08K/day | $- | $- | ▲ +25 days |
| 2021 | 111 days | $8.01 Million | $72.48K/day | $- | $- | ▼ -568 days |
| 2020 | 679 days | $20.57 Million | $30.31K/day | $- | $- | ▲ +456 days |
| 2019 | 223 days | $2.82 Million | $12.65K/day | $- | $- | — |